S Sponholz1, S Bölükbas2, M Schirren2, S Oguzhan2, N Kudelin2, J Schirren2. 1. Klinik für Thoraxchirurgie, Dr. Horst Schmidt Klinik, Helios Kliniken Gruppe, Ludwig-Erhard-Straße 100, 65199, Wiesbaden, Deutschland. Stefan.sponholz@helios-kliniken.de. 2. Klinik für Thoraxchirurgie, Dr. Horst Schmidt Klinik, Helios Kliniken Gruppe, Ludwig-Erhard-Straße 100, 65199, Wiesbaden, Deutschland.
Abstract
INTRODUCTION: The resection of liver and lung metastases from colorectal cancer has not yet been completely investigated. The aim of this study was to investigate the overall survival and prognostic factors for patients with liver and lung metastases from colorectal cancer. METHODS: A retrospective review of a prospective database of 52 patients with liver and lung metastases from colorectal cancer, undergoing metastasectomy with curative intent from 1999-2009 at a single institution was carried out. RESULTS: The mean overall survival (OS) was 64 months. For synchronous liver and lung metastases the mean overall survival was 63 months (5-year survival 54 %) and for metachronous liver and lung metastases 74 months (5-year survival 58 %, p = 0.451). A poor prognostic outcome was observed in cases of localization of the primary tumor in the rectum (OS 81 vs. 38 months, p = 0.004), with multiple lung metastases (≥ 2 metastases, OS 74 vs. 59 months, p = 0.032) and with disease progression after premetastasectomy chemotherapy (OS 74 vs. 63 vs. 15 months, p < 0.001). No influence on overall survival was detected for bilateral lung metastases, thoracic lymph node metastases, disease recurrence and disease-free interval < 36 months. CONCLUSION: Metastasectomy for liver and lung metastases of colorectal cancer is associated with a good overall survival in selected cases. Patients with liver and lung metastases should not be routinely excluded from metastasectomy and patients with thoracic lymph node metastases should also not be routinely excluded. Negative prognostic factors for survival are localization of the tumor in the rectum, multiple metastases and disease progression after premetastasectomy chemotherapy. Patients with disease progression after premetastasectomy chemotherapy should be excluded from metastasectomy.
INTRODUCTION: The resection of liver and lung metastases from colorectal cancer has not yet been completely investigated. The aim of this study was to investigate the overall survival and prognostic factors for patients with liver and lung metastases from colorectal cancer. METHODS: A retrospective review of a prospective database of 52 patients with liver and lung metastases from colorectal cancer, undergoing metastasectomy with curative intent from 1999-2009 at a single institution was carried out. RESULTS: The mean overall survival (OS) was 64 months. For synchronous liver and lung metastases the mean overall survival was 63 months (5-year survival 54 %) and for metachronous liver and lung metastases 74 months (5-year survival 58 %, p = 0.451). A poor prognostic outcome was observed in cases of localization of the primary tumor in the rectum (OS 81 vs. 38 months, p = 0.004), with multiple lung metastases (≥ 2 metastases, OS 74 vs. 59 months, p = 0.032) and with disease progression after premetastasectomy chemotherapy (OS 74 vs. 63 vs. 15 months, p < 0.001). No influence on overall survival was detected for bilateral lung metastases, thoracic lymph node metastases, disease recurrence and disease-free interval < 36 months. CONCLUSION: Metastasectomy for liver and lung metastases of colorectal cancer is associated with a good overall survival in selected cases. Patients with liver and lung metastases should not be routinely excluded from metastasectomy and patients with thoracic lymph node metastases should also not be routinely excluded. Negative prognostic factors for survival are localization of the tumor in the rectum, multiple metastases and disease progression after premetastasectomy chemotherapy. Patients with disease progression after premetastasectomy chemotherapy should be excluded from metastasectomy.
Authors: U Pastorino; M Buyse; G Friedel; R J Ginsberg; P Girard; P Goldstraw; M Johnston; P McCormack; H Pass; J B Putnam Journal: J Thorac Cardiovasc Surg Date: 1997-01 Impact factor: 5.209
Authors: J R Headrick; D L Miller; D M Nagorney; M S Allen; C Deschamps; V F Trastek; P C Pairolero Journal: Ann Thorac Surg Date: 2001-03 Impact factor: 4.330
Authors: Ravi Marudanayagam; Krishnamoorthy Ramkumar; Vivekanandan Shanmugam; Gerald Langman; Pala Rajesh; Chris Coldham; Simon R Bramhall; David Mayer; John Buckels; Darius F Mirza Journal: HPB (Oxford) Date: 2009-12 Impact factor: 3.647
Authors: George Miller; Peter Biernacki; Nancy E Kemeny; Mithat Gonen; Robert Downey; William R Jarnagin; Michael D'Angelica; Yuman Fong; Leslie H Blumgart; Ronald P DeMatteo Journal: J Am Coll Surg Date: 2007-06-27 Impact factor: 6.113
Authors: Stefan Sponholz; Selma Oguzhan; Mesut Mese; Moritz Schirren; Andreas Kirschbaum; Joachim Schirren Journal: Int J Colorectal Dis Date: 2021-03-12 Impact factor: 2.571